Roberts Glore & Co. Inc. IL Makes New Investment in Stryker Corporation $SYK

Roberts Glore & Co. Inc. IL purchased a new position in Stryker Corporation (NYSE:SYK) during the second quarter, Holdings Channel reports. The institutional investor purchased 13,705 shares of the medical technology company’s stock, valued at approximately $4,315,000. Stryker accounts for 1.1% of Roberts Glore & Co. Inc. IL’s investment portfolio, making the stock its 19th largest position.

A number of other hedge funds have also bought and sold shares of the company. Gables Capital Management Inc. bought a new stake in Stryker during the second quarter valued at $25,000. Kilter Group LLC acquired a new stake in Stryker during the 2nd quarter worth about $25,000. Godfrey Financial Associates Inc. bought a new position in shares of Stryker in the 4th quarter worth about $26,000. Sankala Group LLC bought a new position in shares of Stryker in the 4th quarter worth about $26,000. Finally, Compass Financial Management LLC acquired a new position in shares of Stryker in the 2nd quarter valued at about $27,000. Institutional investors own 77.09% of the company’s stock.

Stryker Stock Performance

Shares of SYK opened at $331.06 on Wednesday. Stryker Corporation has a one year low of $281.00 and a one year high of $396.86. The company has a market cap of $126.98 billion, a PE ratio of 34.31, a P/E/G ratio of 2.09 and a beta of 0.76. The stock has a 50-day moving average of $327.80 and a 200-day moving average of $331.95. The company has a debt-to-equity ratio of 0.59, a current ratio of 2.16 and a quick ratio of 1.33.

Stryker (NYSE:SYK) last posted its quarterly earnings results on Thursday, July 30th. The medical technology company reported $3.69 earnings per share for the quarter, topping analysts’ consensus estimates of $3.49 by $0.20. The business had revenue of $6.59 billion for the quarter, compared to the consensus estimate of $6.58 billion. Stryker had a return on equity of 23.63% and a net margin of 14.43%.The firm’s revenue for the quarter was up 9.4% on a year-over-year basis. During the same period in the prior year, the business earned $3.13 EPS. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. On average, equities research analysts predict that Stryker Corporation will post 15.02 EPS for the current fiscal year.

Stryker Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be given a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.1%. The ex-dividend date of this dividend is Wednesday, September 30th. Stryker’s dividend payout ratio is presently 36.48%.

Analysts Set New Price Targets

Several equities research analysts recently commented on the company. Weiss Ratings restated a “hold (c)” rating on shares of Stryker in a research report on Friday, July 31st. Wells Fargo & Company dropped their price target on Stryker from $456.00 to $418.00 and set an “overweight” rating on the stock in a research note on Friday, May 1st. Robert W. Baird set a $385.00 price target on Stryker in a report on Friday, May 1st. Deutsche Bank Aktiengesellschaft set a $315.00 price objective on shares of Stryker in a research report on Friday, May 1st. Finally, Truist Financial lifted their price objective on shares of Stryker from $330.00 to $340.00 and gave the company a “hold” rating in a research note on Friday, July 31st. One research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $386.28.

Insider Transactions at Stryker

In related news, VP Robert S. Fletcher sold 4,544 shares of the stock in a transaction on Thursday, May 28th. The stock was sold at an average price of $306.87, for a total value of $1,394,417.28. Following the transaction, the vice president directly owned 10,582 shares in the company, valued at $3,247,298.34. This trade represents a 30.04% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Ronda E. Stryker sold 300,000 shares of Stryker stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $335.90, for a total transaction of $100,770,000.00. Following the completion of the sale, the director directly owned 2,301,375 shares of the company’s stock, valued at approximately $773,031,862.50. The trade was a 11.53% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 355,370 shares of company stock valued at $119,447,201 over the last ninety days. 4.60% of the stock is owned by company insiders.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.